With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Robert McLean, Senior Program Specialist, Policy and Evaluation, International Development Research Centre (IDRC)
John Gargani, Founder and President, Gargani + Company, Inc.
Johannes F. Linn, Non-resident Senior Fellow, Global Economy and Development Program, Brookings Institution
Vijaya Ramachandran, Senior Fellow, Center for Global Development
ABOUT THE EVENT
Please join us to discuss the new IDRC book Scaling Impact: Innovation for the Public Good. Co-authors, Robert McLean and John Gargani, will discuss the new and practical approach to scaling the positive impacts of research and innovation outlined in the book, based on a review of over 200 IDRC studies and 5 in-depth case explorations.
For organizations and individuals working to change the world for the better, scaling impact is a common goal and a well-founded aim. The world is changing rapidly, and seemingly intractable problems like environmental degradation or accelerating inequality press us to do better for each other and our environment as a global community. Challenges like these appear to demand a significant scale of action, and here the authors argue that a more creative and critical approach to scaling is both possible and essential. To encourage uptake and co-development, the authors present actionable principles that can help organizations and innovators design, manage, and evaluate scaling strategies.
Humanitarian relief must involve, and be accountable to, the crisis-affected people it serves.
Versions of this principle can be found in most foundational humanitarian documents, and it features prominently in recent reform commitments including the 2016 Grand Bargain. Yet the power structures that shape international humanitarian response are not driven by, or accountable to, the people that they exist to serve. They are still engaged more as passive recipients of aid than as a force shaping humanitarian priorities. Living up to the aspiration of people-driven humanitarian action will require uncomfortable – but overdue – changes to the humanitarian system’s incentive structures and power dynamics.
Gautam Rao will talk about his new research, which examines whether evidence changes the beliefs and actions of policy makers. His findings show that policy makers do update their beliefs and do make different policy decisions when presented with new evidence. This research is particularly fascinating for anyone working in policy-influencing roles or in think tanks as it provides direct evidence that providing research information to political leaders can lead to policy change.
The World Bank’s Disease Control Priorities, Third Edition (DCP3) defines a model concept of essential universal health coverage (EUHC) with 218 interventions that provides a starting point for country-specific analysis of priorities. Assuming steady-state implementation by 2030, EUHC in lower-middle-income countries would reduce premature deaths by an estimated 4.2 million per year. Estimated total costs prove substantial: about 9·1% of (current) gross national income (GNI) in low-income countries and 5.2% of GNI in lower-middle-income countries.
Please join the Center for Global Development for this conversation with Devex’s president & editor-in-chief, Raj Kumar, to discuss his book The Business of Changing the World, which has been called the 'go to primer' on the people, ideas and tech disrupting the aid industry. Caroline Atkinson, former head of global policy at Google, will moderate the conversation on how nontraditional models of philanthropy and aid are empowering the world's poorest people to make progress.
Quality affordable generic medicines play a vital role in health systems around the world. Healthy competition from quality generic medicines can help keep prices in check—a shared concern across high-income and low- and middle-income countries. But CGD’s Working Group on the Future of Global Health Procurement found that markets for generic medicines in many low- and middle-income countries are failing. According to the final report, weak and under-resourced regulatory and quality control systems in many countries can often lead healthcare workers and patients to opt for more expensive branded medicines as a proxy for quality.